Immunethep
↗Cantanhede, Portugal
Immunethep is a Portuguese biotechnology company, founded in 2013 as a spin-off of the University of Porto, dedicated to developing anti-bacterial immunotherapies to combat antimicrobial resistance (AMR). The company utilizes its proprietary PIT-ID (Platform for Immunomodulatory Therapies for Infectious Diseases) technology to target a virulence mechanism shared by various life-threatening bacteria.
Their pipeline includes both preventive vaccines and therapeutic monoclonal antibodies designed to restore the host's immune response against pathogens such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Streptococcus species. The company operates from its headquarters and R&D facilities at Biocant Park in Cantanhede, Portugal.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$2.85M
Investors:CARB-X, Portugal Ventures, Venture Catalysts, Beta Capital
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Vaccine, Monoclonal antibody
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Merck & Co. (Research collaboration), CARB-X (Funding and support), PACE (Funding and support)
COMPETITION
Position:Emerging
Competitors:Spero Therapeutics, Bharat Biotech, HOOKIPA Pharma
LEADERSHIP
Key Executives:
Bruno Santos - CEO
Pedro Madureira - CSO
Scientific Founders:Pedro Madureira, Bruno Santos
LINKS
Website:immunethep.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Immunethep and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immunethep. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.